3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Thoracic
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
12
Lymphoma, T-Cell, Cutaneous
5
Mycosis Fungoides
4
Sezary Syndrome
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
28
Nivolumab
14
Ipilimumab
7
Cyclophosphamide
7
spartalizumab
6
atezolizumab
4
Interleukin-2
4
fludarabine
3
durvalumab
3
cemiplimab
3
avelumab
3
aldesleukin
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Immune Checkpoint Inhibitors
3
Docetaxel
3
obinutuzumab
2
epacadostat
2
budigalimab
2
bempegaldesleukin
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
vocimagene amiretrorepvec
1
venetoclax
1
utomilumab
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Immunoglobulin G
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled